News for Healthier Living

Adding Immune Checkpoint Inhibitor to Standard Chemotherapy Regimen Improves Outcomes in Stage 3 Colon Cancer, Study Finds

Combining standard adjuvant chemotherapy with an immune checkpoint inhibitor (atezolizumab) leads to a significant improvement in disease-free survival in a subset of patients with stage 3 colon cancer that is deficient in DNA mismatch repair (dMMR), Dana-Farber Cancer Institute investigator Dr. Jeffrey Meyerhardt and his colleagues report at the 2025 American Society of Clinical Oncology (ASCO) meeting.

June 1, 2025


June 7 2025

June 6 2025

June 5 2025

June 4 2025

June 3 2025

June 2 2025

June 1 2025

May 31 2025

May 30 2025

May 29 2025

May 28 2025

May 27 2025

May 26 2025

May 25 2025

May 24 2025